BASF Plans Amine Facility in Nanjing
PTSM: Pharmaceutical Technology Sourcing and Management
BASF will build a new specialty amines plant at its existing wholly owned site in Nanjing Chemical Industry Park in China.
BASF will build a new specialty amines plant at its existing wholly owned site in Nanjing Chemical Industry Park in China, the company announced in a Sept. 25, 2017 press release. The new multi-product plant can manufacture 21,000 metric tons per year and further extends BASF’s amines portfolio at the specialty amines complex in Nanjing. The plant is scheduled to come on stream in 2019 and will mainly produce 1,2-Propylenediamine (1,2-PDA), n-Octylamine (n-OA), and Polyetheramine (PEA). 1,2-PDA is a building block in the manufacture of pharmaceuticals as well as other chemicals.
“This investment will help us to meet the increasing Asia Pacific demand for specialty amines used as intermediates in a diverse range of industries …,” said Narayan Krishnamohan, senior vice-president, Intermediates Asia Pacific, BASF, in the press release. “Through this expansion, we will be able to better serve our customers in Asia Pacific with steady and timely supply of quality products.”
BASF also has manufacturing capacities for both 1,2-PDA and n-OA at its Ludwigshafen Verbund site in Germany.
Source: BASF
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
